Kevin Reyes is the Chair of the San Diego office’s Corporate Department.
Kevin represents both private and public companies in a wide variety of corporate matters, including mergers and acquisitions, public securities offerings, corporate governance, venture financings, and securities law and stock exchange compliance matters. Kevin also has significant experience with periodic and current reporting requirements and proxy rules, and he co-authors the Annual Meeting Handbook, which is published annually and distributed nationwide.
While attending the University of Southern California Gould School of Law, Kevin served as a judicial extern for Judge Virginia A. Phillips in the US District Court for the Central District of California.
Experience
Kevin has advised on a broad range of corporate transactions, including numerous public and private company mergers, acquisitions, asset sales, and investments.
Significant matters include representing:
Callaway Golf in its:
US$2 billion stock-for-stock merger with Topgolf International
US$75 million acquisition of Ogio International
US$125 million acquisition of TravisMathew
€418 million acquisition of German-based Jack Wolfskin
US$29 million acquisition of BigShots Golf
Extra Space Storage in its:
US$47 billion stock-for-stock merger with Life Storage
US$590 million acquisition of Storage Express
US$1.4 billion acquisition of SmartStop Self Storage
Bridge Investment Group in its US$320 million acquisition of Newbury Partners
Viasat in its:
US$222 million stock-for-stock merger with RigNet
US$62 million acquisition of NetNearU
BioMed Realty Trust in its US$8 billion acquisition by affiliates of The Blackstone Group
Impact Biomedicines in its acquisition by Celgene Corporation for up to US$7 billion
Alphatec Spine in its:
Acquisition of French-based EOS imaging via public tender
US$80 million sale of its international business to Globus Medical
Excel Trust in its US$2 billion acquisition by affiliates of The Blackstone Group
Ligand Pharmaceuticals in its US$178 million acquisition of Open Monoclonal Technology
Agility Clinical in its sale to Precision Medical Group for proceeds of up to US$46 million
Aratana Therapeutics in its:
€33.3 million stock acquisition of Okapi Sciences
US$30 million cash and stock merger with Vet Therapeutics
Neurelis in its acquisition of Aegis Therapeutics
Pulse Electronics in a US$26 million going private transaction with Oaktree Capital Management
Zavante Therapeutics in its stock-for-stock sale to Nabriva Therapeutics plc for up to US$125 million
Kevin has also advised numerous companies, underwriters, and investors on various public and private financings, including initial public offerings, PIPE financings, venture financings, private equity and debt offerings, and follow-on, and secondary public offerings, including representing:
Bridge Investment Group in its US$300 million initial public offering
Callaway Golf in connection with its follow-on offerings of equity and debt, raising more than US$250 million
Crinetics Pharmaceuticals in its US$117 million initial public offering and several equity follow-on offerings and private placement financings
Essex Property Trust in senior notes offerings and at-the-market equity offerings, raising more than US$2 billion
Extra Space Storage in equity and debt offerings, raising more than US$875 million
Gossamer Bio in its US$317 million initial public offering and several equity and debt follow-on offerings and private placement financings
Neurelis in its preferred stock financings with LYZZ Capital, HBM Healthcare Investments, and China Medical Systems, raising over US$150 million
SkyWest Airlines in connection with various capital raising matters
Viasat in equity and debt offerings, raising more than US$1 billion
Virgin Galactic Holdings in its at-the-market equity offerings
Airgain in its US$12 million initial public offering
Alphatec Spine in multiple PIPE financings, raising over US$150 million
Zavante Therapeutics in its Series A financing with Frazier Healthcare Partners, Longitude Capital, and Aisling Capital
A number of investment banks, including Barclays, BofA Merrill Lynch, BMO, Jefferies, J.P Morgan, Piper Jaffray, and Stifel, in public offerings of equity securities for life sciences companies, including Applied Genetic Technologies Corporation, Glycomimetics, ACADIA Pharmaceuticals, Biocryst Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, Neurocrine Biosciences, and Sarepta Therapeutics
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.
